BioCentury
ARTICLE | Clinical News

Eureka's ET140202 leads to tumor regression in Phase I for HCC

Jaime De Leon
September 21, 2018 4:43 PM GMT
Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Eureka Therapeutics Inc.